3'-Methoxydaidzein is a dual isoflavone and Sodium Channel inhibitor. 3'-Methoxydaidzein inhibited NaV1.7, NaV1.8 and NaV1.3 with IC50 of 181 nM, 397 nM and 505 nM, respectively. 3'-Methoxydaidzein was specific for collagen-induced platelet aggregation with IC50 values of 12.3 and 61.5µM, respectively. 3'-Methoxydaidzein acts as an analgesic by inhibiting voltage-gated sodium channels. 3'-Methoxydaidzein showed antioxidant activity and antiplatelet aggregation activity.

3'-Methoxydaidzein, their antioxidant activities were investigated and compared with butylated hydroxyluene (BHT) and α±-tocopherol. The results showed that 3'-Methoxydaidzein had antioxidant activity. When the individual components (0.02%) were mixed with 0.02% BHT, or 0.02% α±-tocopherol, their protection factor was increased, but there was no synergistic effect. When the individual component had 4 ppm added Fe3+, 3'-Methoxydaidzein had antioxidant activity. Their antioxidant activities were tested by an oxidative stability instrument (OSI) at 100°C.[1]

3'-Methoxydaidzein shows strong analgesic potential without inducing addiction through inhibiting subtypes NaV1.7, NaV1.8 and NaV1.3 with the IC50 of 181 ± 14, 397 ± 26, and 505 ± 46 nmol·L-1, respectively, providing a promising compound or parent structure for the treatment of pain pathologies. This study reveals a pain-alleviating mechanism of dietary isoflavones and may provide a convenient avenue to alleviate pain.[2]